» Articles » PMID: 35614924

Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders

Overview
Journal Front Neurol
Specialty Neurology
Date 2022 May 26
PMID 35614924
Authors
Affiliations
Soon will be listed here.
Abstract

Various surgical techniques and pharmaceutical treatments have been developed to improve the current technologies of treating brain diseases. Focused ultrasound (FUS) is a new brain stimulation modality that can exert a therapeutic effect on diseased brain cells, with this effect ranging from permanent ablation of the pathological neural circuit to transient excitatory/inhibitory modulation of the neural activity depending on the acoustic energy of choice. With the development of intraoperative imaging technology, FUS has become a clinically available noninvasive neurosurgical option with visual feedback. Over the past 10 years, FUS has shown enormous potential. It can deliver acoustic energy through the physical barrier of the brain and eliminate abnormal brain cells to treat patients with Parkinson's disease and essential tremor. In addition, FUS can help introduce potentially beneficial therapeutics at the exact brain region where they need to be, bypassing the brain's function barrier, which can be applied for a wide range of central nervous system disorders. In this review, we introduce the current FDA-approved clinical applications of FUS, ranging from thermal ablation to blood barrier opening, as well as the emerging applications of FUS in the context of pain control, epilepsy, and neuromodulation. We also discuss the expansion of future applications and challenges. Broadening FUS technologies requires a deep understanding of the effect of ultrasound when targeting various brain structures in diverse disease conditions in the context of skull interface, anatomical structure inside the brain, and pathology.

Citing Articles

Breaking Barriers in Huntington's Disease Therapy: Focused Ultrasound for Targeted Drug Delivery.

Helal M, Ibrahim A, Beddor A, Kashbour M Neurochem Res. 2025; 50(1):68.

PMID: 39751928 PMC: 11698766. DOI: 10.1007/s11064-024-04302-w.


Predicting Post-Operative Side Effects in VIM MRgFUS Based on THalamus Optimized Multi Atlas Segmentation (THOMAS) on White-Matter-Nulled MRI: A Retrospective Study.

Oshima S, Kim A, Sun X, Rifi Z, Cross K, Fu K AJNR Am J Neuroradiol. 2024; 46(2):330-340.

PMID: 39730158 PMC: 11878955. DOI: 10.3174/ajnr.A8448.


A comparative study of experimental and simulated ultrasound beam propagation through cranial bones.

Krokhmal A, Simcock I, Simcock I, Treeby B, Martin E Phys Med Biol. 2024; 70(2.

PMID: 39700626 PMC: 11734220. DOI: 10.1088/1361-6560/ada19d.


Reversible Ca signaling and enhanced paracellular transport in endothelial monolayer induced by acoustic bubbles and targeted microbeads.

Lin J, Qiao C, Jiang H, Liu Z, Hu Y, Liu W Ultrason Sonochem. 2024; 112():107181.

PMID: 39638739 PMC: 11743859. DOI: 10.1016/j.ultsonch.2024.107181.


The therapeutic potential of low-intensity focused ultrasound for treating substance use disorder.

Olaitan G, Lynch W, Venton B Front Psychiatry. 2024; 15:1466506.

PMID: 39628494 PMC: 11612502. DOI: 10.3389/fpsyt.2024.1466506.


References
1.
Mesiwala A, Farrell L, Wenzel H, Silbergeld D, Crum L, Winn H . High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med Biol. 2002; 28(3):389-400. DOI: 10.1016/s0301-5629(01)00521-x. View

2.
Davidson B, Hamani C, Rabin J, Goubran M, Meng Y, Huang Y . Magnetic resonance-guided focused ultrasound capsulotomy for refractory obsessive compulsive disorder and major depressive disorder: clinical and imaging results from two phase I trials. Mol Psychiatry. 2020; 25(9):1946-1957. DOI: 10.1038/s41380-020-0737-1. View

3.
Lake A, Xu Z, Wilkinson J, Cain C, Roberts W . Renal ablation by histotripsy--does it spare the collecting system?. J Urol. 2008; 179(3):1150-4. DOI: 10.1016/j.juro.2007.10.033. View

4.
Park S, Kim M, Jung H, Chang W, Choi H, Rachmilevitch I . One-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. Front Oncol. 2020; 10:1663. PMC: 7511634. DOI: 10.3389/fonc.2020.01663. View

5.
Kornstein S, Schneider R . Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001; 62 Suppl 16:18-25. View